[go: up one dir, main page]

UY31010A1 - Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion - Google Patents

Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion

Info

Publication number
UY31010A1
UY31010A1 UY31010A UY31010A UY31010A1 UY 31010 A1 UY31010 A1 UY 31010A1 UY 31010 A UY31010 A UY 31010A UY 31010 A UY31010 A UY 31010A UY 31010 A1 UY31010 A1 UY 31010A1
Authority
UY
Uruguay
Prior art keywords
estradiol
pharmaceutical product
drospirenona
kit
elements
Prior art date
Application number
UY31010A
Other languages
English (en)
Inventor
Joachim Marr
Bernd Doesterberg
Rolf Schoermann
Hartmut Blode
Vladimir Hanes
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39745001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY31010A1 publication Critical patent/UY31010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un producto farmacéutico combinado de al menos 21 unidades de dosificacion diarias consecutivas que contienen entre 2,0 mg y 3,0 mg de drospirenona y entre 1,0 y 2,0 mg de 17 B(Bet)-estradiol en cada unidad de dosifiacion diaria seguido por unidades de dosificacion diarias intermitentes que contienen la misma cantidad, o una cantidad menor, de drospirenona ( es decir, entre 0,5mg y 3,0 mg) como unidades de dosificacion diarias consecutivas, en donde cada unidad de dosifiacion diaria intermitente está prededida por al menos un día sin administracion de drospirenona.
UY31010A 2007-04-05 2008-04-07 Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion UY31010A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91032607P 2007-04-05 2007-04-05
US3528508P 2008-03-10 2008-03-10
US4049408P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
UY31010A1 true UY31010A1 (es) 2008-11-28

Family

ID=39745001

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31010A UY31010A1 (es) 2007-04-05 2008-04-07 Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion

Country Status (15)

Country Link
US (1) US20090023693A1 (es)
EP (1) EP2150257A2 (es)
JP (1) JP2010523512A (es)
CN (1) CN101674837A (es)
AR (1) AR065971A1 (es)
AU (1) AU2008235006A1 (es)
BR (1) BRPI0810049A2 (es)
CA (1) CA2683093A1 (es)
CL (1) CL2008000999A1 (es)
IL (1) IL201302A0 (es)
MX (1) MX2009010763A (es)
PE (1) PE20090805A1 (es)
TW (1) TW200904452A (es)
UY (1) UY31010A1 (es)
WO (1) WO2008122439A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
JP5951480B2 (ja) 2009-04-14 2016-07-13 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ オンデマンド避妊方法
ES2533584T3 (es) * 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Formas de dosificación oral sólidas de dosis baja para TSH
BR112012026115B1 (pt) * 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
CN108025014B (zh) * 2015-06-23 2021-10-22 莱昂实验室制药股份有限公司 用于过重女性患者的基于屈螺酮的避孕药

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
JP2010523512A (ja) 2010-07-15
MX2009010763A (es) 2009-10-28
CA2683093A1 (en) 2008-10-16
US20090023693A1 (en) 2009-01-22
AU2008235006A1 (en) 2008-10-16
CN101674837A (zh) 2010-03-17
IL201302A0 (en) 2010-05-31
WO2008122439A3 (en) 2009-07-23
TW200904452A (en) 2009-02-01
AR065971A1 (es) 2009-07-15
PE20090805A1 (es) 2009-07-25
CL2008000999A1 (es) 2008-10-10
BRPI0810049A2 (pt) 2015-05-05
WO2008122439A2 (en) 2008-10-16
EP2150257A2 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
MY160456A (en) Benzodiazepine bromodomain inhibitor
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
UY31010A1 (es) Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
MY139913A (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
TW200642704A (en) Oral drug delivery system and methods of use thereof
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
TW200744672A (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
TR200903036A2 (tr) Tiyokolşikozit ve non-steroidal anti-enflamatuar ilaç kombinasyonları
UY31887A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la cardioversión
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2009005329A (es) Composiciones farmaceuticas anticonvulsivas.
PE20141688A1 (es) Combinacion farmaceutica antineuritica y composiciones

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170919